Aleglitazar (BioDeep_00000752560)
代谢物信息卡片
Aleglitazar
化学式: C24H23NO5S (437.12968680000006)
中文名称: (S)-2-甲氧基-3-[4-[2-(5-甲基-2-苯基恶唑-4-基)乙氧基]苯并[B]噻吩-7-基]丙酸
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC(C(=O)O)OC
InChI: InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D08845
- PubChem: 10274777
- DrugBank: DB08915
- ChEMBL: CHEMBL519504
- CAS: 475479-34-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Chun-Liu Han, Chang-Zhi Qu. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Journal of cardiovascular pharmacology.
2020 04; 75(4):351-357. doi:
10.1097/fjc.0000000000000796. [PMID: 31929323] - Jeroen V Koomen, Hiddo J L Heerspink, Ilse C Schrieks, Gregory G Schwartz, A Michael Lincoff, Stephen J Nicholls, Anders Svensson, Hans Wedel, Arlette Weichert, Diederick E Grobbee, Jasper Stevens. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Diabetes, obesity & metabolism.
2020 01; 22(1):30-38. doi:
10.1111/dom.13862. [PMID: 31468659] - Valérie Boujon, Ria Uhlemann, Stephanie Wegner, Matthew B Wright, Ulrich Laufs, Matthias Endres, Golo Kronenberg, Karen Gertz. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Journal of molecular medicine (Berlin, Germany).
2019 08; 97(8):1127-1138. doi:
10.1007/s00109-019-01801-0. [PMID: 31147725] - Martin Bopst, Elke-Astrid Atzpodien. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Regulatory toxicology and pharmacology : RTP.
2017 Jun; 86(?):107-116. doi:
10.1016/j.yrtph.2017.03.003. [PMID: 28274810] - Sigrid Cj van Steen, Ilse C Schrieks, Joost Bl Hoekstra, A Michael Lincoff, Jean-Claude Tardif, Linda G Mellbin, Lars Rydén, Diederick E Grobbee, J Hans DeVries. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
European journal of preventive cardiology.
2017 05; 24(8):858-866. doi:
10.1177/2047487317692664. [PMID: 28186441] - A O Stirban, M Andjelkovic, T Heise, L Nosek, A Fischer, A Gastaldelli, M Herz. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Diabetes, obesity & metabolism.
2016 07; 18(7):711-5. doi:
10.1111/dom.12620. [PMID: 26663152] - Marika Massaro, Egeria Scoditti, Mariangela Pellegrino, Maria Annunziata Carluccio, Nadia Calabriso, Martin Wabitsch, Carlo Storelli, Matthew Wright, Raffaele De Caterina. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Pharmacological research.
2016 05; 107(?):125-136. doi:
10.1016/j.phrs.2016.02.027. [PMID: 26976796] - R R Henry, J B Buse, H Wu, L Durrwell, R Mingrino, K Jaekel, B El Azzouzi, M Andjelkovic, M Herz. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Diabetes, obesity & metabolism.
2015 Jun; 17(6):560-565. doi:
10.1111/dom.12455. [PMID: 25728612] - Luis Ruilope, Markolf Hanefeld, A Michael Lincoff, Giancarlo Viberti, Sylvie Meyer-Reigner, Nadejda Mudie, Dominika Wieczorek Kirk, Klas Malmberg, Matthias Herz. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
BMC nephrology.
2014 Nov; 15(?):180. doi:
10.1186/1471-2369-15-180. [PMID: 25407798] - A Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, Stephen J Nicholls, Lars Rydén, Bruce Neal, Klas Malmberg, Hans Wedel, John B Buse, Robert R Henry, Arlette Weichert, Ruth Cannata, Anders Svensson, Dietmar Volz, Diederick E Grobbee. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
JAMA.
2014 Apr; 311(15):1515-25. doi:
10.1001/jama.2014.3321. [PMID: 24682069] - A Michael Lincoff, Jean-Claude Tardif, Bruce Neal, Stephen J Nicholls, Lars Rydén, Gregory G Schwartz, Klas Malmberg, John B Buse, Robert R Henry, Hans Wedel, Arlette Weichert, Ruth Cannata, Diederick E Grobbee. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
American heart journal.
2013 Sep; 166(3):429-34. doi:
10.1016/j.ahj.2013.05.013. [PMID: 24016490] - A Bénardeau, P Verry, E-A Atzpodien, J M Funk, M Meyer, J Mizrahi, M Winter, M B Wright, S Uhles, E Sebokova. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Diabetes, obesity & metabolism.
2013 Feb; 15(2):164-74. doi:
10.1111/dom.12006. [PMID: 22958363] - J P H Wilding. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Diabetes, obesity & metabolism.
2012 Nov; 14(11):973-82. doi:
10.1111/j.1463-1326.2012.01601.x. [PMID: 22443197] - Stefan Sturm, Michael Seiberling, Idelette Weick, Axel Paehler, Christoph Funk, Thorsten Ruf. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Clinical therapeutics.
2012 Feb; 34(2):420-9. doi:
10.1016/j.clinthera.2011.12.009. [PMID: 22244809] - E Rozema, A G Atanasov, N Fakhrudin, J Singhuber, U Namduang, E H Heiss, G Reznicek, C W Huck, G K Bonn, V M Dirsch, B Kopp. Selected Extracts of Chinese Herbal Medicines: Their Effect on NF-κB, PPARα and PPARγ and the Respective Bioactive Compounds.
Evidence-based complementary and alternative medicine : eCAM.
2012; 2012(?):983023. doi:
10.1155/2012/983023. [PMID: 22675394] - Renée Deehan, Pia Maerz-Weiss, Natalie L Catlett, Guido Steiner, Ben Wong, Matthew B Wright, Gil Blander, Keith O Elliston, William Ladd, Maria Bobadilla, Jacques Mizrahi, Carolina Haefliger, Alan Edgar. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
PloS one.
2012; 7(4):e35012. doi:
10.1371/journal.pone.0035012. [PMID: 22514701] - Matthias Herz, Flavio Gaspari, Norberto Perico, Giancarlo Viberti, Teresa Urbanowska, Michael Rabbia, Dominika Wieczorek Kirk. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
International journal of cardiology.
2011 Sep; 151(2):136-42. doi:
10.1016/j.ijcard.2010.08.037. [PMID: 20837369] - Xinlun Tian, Jinmei Luo, Kai-Feng Xu, Lan Wang, Jiong Zhou, Ruie Feng, Yaosong Gui, Juan Wang, Wenbing Xu, Yi Xiao, Yuanjue Zhu. Impaired lipid metabolism in idiopathic pulmonary alveolar proteinosis.
Lipids in health and disease.
2011 Apr; 10(?):54. doi:
10.1186/1476-511x-10-54. [PMID: 21486485] - Jan Westerink, Frank L J Visseren. Pharmacological and non-pharmacological interventions to influence adipose tissue function.
Cardiovascular diabetology.
2011 Jan; 10(?):13. doi:
10.1186/1475-2840-10-13. [PMID: 21276223] - Barbara C Hansen, Xenia T Tigno, Agnes Bénardeau, Markus Meyer, Elena Sebokova, Jacques Mizrahi. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Cardiovascular diabetology.
2011 Jan; 10(?):7. doi:
10.1186/1475-2840-10-7. [PMID: 21251281] - Adam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, Paul Jordan. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Expert opinion on investigational drugs.
2011 Jan; 20(1):3-12. doi:
10.1517/13543784.2010.539559. [PMID: 21114416] - Salvatore Salomone. Pleiotropic effects of glitazones: a double edge sword?.
Frontiers in pharmacology.
2011; 2(?):14. doi:
10.3389/fphar.2011.00014. [PMID: 21687509] - Beata Lecka-Czernik. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
IDrugs : the investigational drugs journal.
2010 Nov; 13(11):793-801. doi:
NULL. [PMID: 21046527] - Jonathan Goldwasser, Pazit Y Cohen, Eric Yang, Patrick Balaguer, Martin L Yarmush, Yaakov Nahmias. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha.
PloS one.
2010 Aug; 5(8):e12399. doi:
10.1371/journal.pone.0012399. [PMID: 20811644] - P Sanwald-Ducray, X Liogier D'ardhuy, C Jamois, L Banken. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Clinical pharmacology and therapeutics.
2010 Aug; 88(2):197-203. doi:
10.1038/clpt.2009.259. [PMID: 20336066] - Matthew A Cavender, A Michael Lincoff. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2010; 10(4):209-16. doi:
10.2165/11539500-000000000-00000. [PMID: 20653327] - Robert R Henry, A Michael Lincoff, Sunder Mudaliar, Michael Rabbia, Cathy Chognot, Matthias Herz. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Lancet (London, England).
2009 Jul; 374(9684):126-35. doi:
10.1016/s0140-6736(09)60870-9. [PMID: 19515415]